Article by Disease | Signal Transduction through JAK-STAT and NF-κB Regulated Pim-1 Kinase: Novel Target for Anticancer Leads

Bentham Oncology Collection | Oncology | Bladder Cancer 

 

Graphical Abstract:

 

 

Abstract:

Background: Signal transduction is a process where a chemical or physical signal is transmitted from extracellular to the intracellular nuclear matrix as a series of molecular events, most commonly protein phosphorylation which ultimately result in a response. At the molecular level, such responses include changes in the transcription or translation of genes, and posttranslational and conformational changes in proteins, as well as changes in their location. These molecular events are the basic mechanisms of controlling cell growth, proliferation, metabolism and many other processes. In multi-cellular organisms, signal transduction pathways evolve to regulate cell communication in various ways. One of the important signal transduction occurs through JAK-STAT and NF-κB regulated Pim-1 kinase expression.

Methods: Major pathways such as JAK-STAT and NF-κB signaling are involved as the targets of Pim-1 kinase activities including cell cycle progression, mitotic cell division, oncogenic transcription, apoptosis and metastatic invasion. There are three target points in JAK –STAT systems including the inhibition of activated JAK via phosphorylation, STAT –STAT dimerization and the entry of activated STAT components for nuclear binding. NF-κB signaling is regulated by IKK enzyme proteasomal degradation and translocation of activated NF-κB complex into nuclear domain for DNA transcription and cellular expression. A number of inhibitors were designed to inhibit these major drug target points of activated JAK-STAT and NF-kB signaling cascades.

Results: Pim denotes Proviral insertion in murine. It was reported that a wide range of human cancers including bladder cancer, colorectal cancer, head and neck cancer and hematological malignancies such as leukemia and lymphomas form due to over-expression of PIM1 via JAK-STAT and NF-κB signaling cascades. An attempt has been made in the present review to focus various potent inhibitors for the inhibition of JAK-STAT and NF-κB signaling targets. These inhibitors are in clinical trials or to be progressed in the clinical investigation.

Conclusion: Incorrect regulation of cytokine-mediated activation of JAK-STAT and NF-κB produces abnormal expression of Pim -1 kinase and solid cancer. Phosphorylated JAKs can induce transcription of target genes and NF-κB acts as a regulator of a gene that can control cell proliferation and cell survival. Therefore, JAK-STAT and NF- κB regulated Pim-1 kinase is a novel target for anticancer leads and these leads can be used to design a template as an anticancer agent. Further clinical studies can be carried out to discover new novel congeneric entities.

 

Find out more at: http://www.eurekaselect.com/node/160178/article

New Issue :: Current Protein & Peptide Science (Volume: 19, Issue: 11)

 

Current Protein & Peptide Science publishes review articles on specific aspects involving proteins, peptides, and interactions between the enzymes, the binding interactions of hormones and their receptors; the properties of transcription factors and other molecules that regulate gene expression; the reactions leading to the immune response; the process of signal transduction; the structure and function of proteins involved in the cytoskeleton and molecular motors; the properties of membrane channels and transporters; and the generation and storage of metabolic energy. In addition, reviews of experimental studies of protein folding and design are given special emphasis.

 

cpps.jpg

Articles from the journal Current Protein & Peptide Science Volume 19, Issue 11:

 

For details on the articles, please visit this link ::  https://bit.ly/2Ob67Tp

Upcoming Thematic Issue – Signal Transduction, Targeted Therapy and Cancer: from Bench to Clinics

Hottopic-CPD-Matilde-Y

For journal Info: http://benthamscience.com/journals/current-pharmaceutical-design/

Most Cited Article:::HSP90 Inhibitors: Current Development and Potential in Cancer Therapy

Author(s): Katerina Sidera and Evangelia Patsavoudi

Abstract: In the last decade, the molecular chaperone HSP90 has emerged as an important target in cancer therapeutics and has subsequently become the focus of several drug discovery and development efforts. The first-in-class HSP90 inhibitor 17-AAG entered into Phase I clinical trial in 1999. Today 13 HSP90 inhibitors representing multiple drug classes, with different modes of action, are undergoing clinical evaluation. The present review will highlight the involvement of HSP90 in regulating and maintaining the transformed phenotype, provide an overview on current HSP90 inhibitors and further update on the most relevant patents which have recently appeared in the literature.

– See more at: http://beta.eurekaselect.com/108016/article#sthash.pL1Ztlaw.dpuf


This article is from the journal Recent Patents on Anti-Cancer Drug Discovery

Highlighted Article Of the Journal: Current Signal Transduction Therapy

CSTT-Articles

For details, visit: http://benthamscience.com/journal/index.php?journalID=cstt

Current Drug Targets

Dr. Faratian and Harrison present a series of articles on the use of Molecular Pathology in personalising therapy for patients with neoplastic and non-neoplastic disease in the upcoming issue. The articles cover genomic, post-genomic, and systems-based approaches to personalised medicine, with a focus on application in the clinic for real cancer patients.

The use of Molecular Pathology in personalising therapy
The use of Molecular Pathology in personalising therapy

 

Dr. Masatoshi Kitagawa edited a special issue on ‘Cell Cycle Control and Cell Fate’ for coming issue of the journal. Here is the brief introduction.

Cell cycle control is important for not only growth and arrest, but also cell fate determination including differentiation, stemness, malignant transformation, senescence and apoptosis. The special issues picks up several processes or pathways regulating “Cell cycle control and cell fate” such as ubiquitin system, signal transduction, chromatin regulation, non-coding RNA, licensing, EMT, senescence, RB- and p53-pathway. I believe that they are attractive as drug targets for not only cancer but also various human diseases.

Cell Cycle Control and Cell Fate
Cell Cycle Control and Cell Fate

 

http://benthamscience.com/cdt/